Which period do DocMorris’s latest results cover?

The results cover the first half of 2026, with comparisons against the first half of 2025. The announcement also refers to performance in the second quarter and the first weeks of the third quarter.

How much did DocMorris’s external revenue and revenue increase in the first half of 2026?

External revenue rose by 12.5 per cent year-on-year to CHF 627.8 million, while revenue increased by 13.4 per cent to CHF 599.2 million. DocMorris said all segments and business areas contributed to the growth.

How did DocMorris’s adjusted EBITDA change in the first half of 2026?

Adjusted EBITDA improved by CHF 17.9 million year-on-year to minus CHF 10.9 million in the first half of 2026. It also improved from minus CHF 6.3 million in the first quarter to minus CHF 4.6 million in the second quarter.

What affected DocMorris’s reported EBITDA in the first half of 2026?

Reported EBITDA was minus CHF 20.0 million, including one-off extraordinary costs of CHF 7.6 million. DocMorris said these costs related, among other things, to implementing its AI-First strategy and closing the Ludwigshafen site, and that the expenses would be largely offset in the second half of the year through resulting cost savings.

What drove growth in DocMorris’s prescription medicines business?

Revenue from prescription medicines, or Rx, rose by 38.3 per cent in the first half of 2026 and by 45.8 per cent in the second quarter. DocMorris attributed the development to higher customer loyalty and repeat order rates, a substantial rise in new customers and lower customer acquisition costs.

How many active Rx customers did DocMorris have and how did that figure change?

The number of active Rx customers rose by 7.1 per cent from the first to the second quarter and by 15.6 per cent year-on-year in the first half of 2026. DocMorris defines these as customers supplied directly or through its partners.

What is DocMorris’s updated full-year Rx growth expectation for 2026?

DocMorris now expects Rx growth of around 40 per cent for the full year, compared with its previous expectation of around 20 per cent. The company said the Rx growth trend accelerated in the first weeks of the third quarter.

How did DocMorris’s Digital Services business perform in the first half of 2026?

Digital Services revenue rose by 71.4 per cent in the first half of 2026, while EBITDA doubled. Digital Services comprises TeleClinic, Retail Media and Marketplace; TeleClinic revenue rose by 48 per cent and the number of treatments increased by 51 per cent compared with the same period last year.

What is DocMorris’s updated 2026 guidance for revenue, adjusted EBITDA and capital expenditure?

DocMorris now guides to external revenue growth of 9 to 13 per cent, adjusted EBITDA of minus CHF 10 million to minus CHF 17.5 million, and capital expenditure below CHF 30 million. The previous ranges were mid-single-digit to low teens percentage range for external revenue growth, minus CHF 10 million to minus CHF 25 million for adjusted EBITDA, and around CHF 30 million for capital expenditure.

What does DocMorris say about its breakeven outlook?

Management confirms the target of reaching EBITDA breakeven in the second half of 2026 and free cash flow breakeven in the course of 2027. CEO Walter Hess said the first-half performance allowed the company to raise its full-year revenue and adjusted EBITDA guidance, while CFO Daniel Wüest said the results and the first weeks of the third quarter gave management further confidence in reaching EBITDA breakeven in the second half of 2026.

What does DocMorris do and how does its business operate?

DocMorris AG is a Swiss-based company operating in online pharmacy, telemedicine and marketplace services, with brands in Germany and other European countries. Its deliveries are mainly handled through an automated logistics centre in Heerlen, the Netherlands, while TeleClinic connects patients with more than 6,500 doctors.

Where are DocMorris AG shares listed and what is the ticker?

The shares of DocMorris AG are listed on the SIX Swiss Exchange. The source gives securities number 4261528, ISIN CH0042615283 and ticker DOCM.

What are the next scheduled events for DocMorris?

DocMorris lists a Q3/2026 trading update for 15 October 2026 and a Capital Markets Day in Heerlen on 12 November 2026. Further scheduled events are Sales 2026 on 19 January 2027, 2026 full-year results and outlook 2027 on 18 March 2027, a Q1/2027 trading update on 15 April 2027 and the Annual General Meeting in Zurich on 12 May 2027.

Home
News Intelligence
DocMorris AG
DocMorris raises 2026 guidance after first-half Rx and Digital Services growth

Back to all DocMorris AG press releases

DocMorris AG

SIX:DOCM

DocMorris raises 2026 guidance after first-half Rx and Digital Services growth

Published Wednesday, 19 August 2026, 05:00 AM

Get alerts

Plain English summaries when DocMorris AG announces news.

At a glance

Company: DocMorris AG
Listings: SIX:DOCM
Announcement type: Financial results
Published: Wednesday, 19 August 2026, 05:00 AM
Reporting period: first half of 2026
Source announcement: eqs-news.com

Key figures
Measure	Figure	Period	Compared with
External revenue	CHF 627.8 million	the first half of 2026	12.5 per cent vs year-on-year
Revenue	CHF 599.2 million	the first half of 2026	13.4 per cent vs year-on-year
Adjusted EBITDA	minus CHF 10.9 million	the first half of 2026	CHF 17.9 million vs year-on-year
EBITDA	minus CHF 4.6 million	the second quarter of 2026	minus CHF 6.3 million in the first quarter of 2026

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Video summary 1 minute 55 seconds

The video covers the same ground as the plain English summary below.

Announcement Summary

DocMorris AG (DOCM) reported first-half results and raised its 2026 guidance after performance across its Rx and Digital Services businesses.

External revenue was CHF 627.8 million in H1 2026, with 12.5 per cent year-on-year growth; revenue was CHF 599.2 million, with 13.4 per cent growth.
Adjusted EBITDA was minus CHF 10.9 million, and the company reported a CHF 17.9 million year-on-year improvement; EBITDA was minus CHF 20.0 million.
Rx revenue growth was 38.3 per cent in the first half, while second-quarter growth was 45.8 per cent; DocMorris now expects around 40 per cent for 2026.
Digital Services revenue growth was 71.4 per cent in the first half; DocMorris now expects more than 50 per cent for 2026.
2026 guidance: external revenue growth 9 to 13 per cent, adjusted EBITDA minus CHF 10 million to minus CHF 17.5 million, capital expenditure below CHF 30 million.
Management confirmed its target of EBITDA breakeven in the second half of 2026 and free cash flow breakeven in the course of 2027.

DocMorris said EBITDA included CHF 7.6 million in one-off extraordinary costs, including AI-First strategy implementation and Ludwigshafen site closure; these expenses will be largely offset in the second half.

Investor FAQs

DocMorris reported continued revenue momentum in the first half of 2026 and increased all elements of its 2026 guidance. External revenue rose 12.5 per cent year-on-year, while adjusted EBITDA improved by CHF 17.9 million to minus CHF 10.9 million.

Source announcement

Company: DocMorris AG
Title: DocMorris with strong growth momentum in Rx and Digital Services in the first half of the year and guidance increase
Published: Wednesday, 19 August 2026, 05:00 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…